about
Differential pharmacology and clinical utility of empagliflozin in type 2 diabetesMetformin revisited: Does this regulator of AMP-activated protein kinase secondarily affect bone metabolism and prevent diabetic osteopathyDiabetes, bone and glucose-lowering agents: clinical outcomes.Obesity, Type 2 Diabetes and Bone in Adults.Impact of Sodium-Glucose Cotransporter 2 Inhibitors on Nonglycemic Outcomes in Patients with Type 2 Diabetes.Succinate and its G-protein-coupled receptor stimulates osteoclastogenesis.Comparisons of weight changes between sodium-glucose cotransporter 2 inhibitors treatment and glucagon-like peptide-1 analogs treatment in type 2 diabetes patients: A meta-analysis.Safety and Tolerability of Empagliflozin in Patients with Type 2 Diabetes: Pooled Analysis of Phase I-III Clinical Trials.SGLT2 inhibitor therapy improves blood glucose but does not prevent diabetic bone disease in diabetic DBA/2J male mice.Evaluation of Bone Mineral Density and Bone Biomarkers in Patients With Type 2 Diabetes Treated With Canagliflozin.A Safety Evaluation of Empagliflozin for the Treatment of Type 2 Diabetes.PPARG Post-translational Modifications Regulate Bone Formation and Bone Resorption.Safe and pragmatic use of sodium-glucose co-transporter 2 inhibitors in type 2 diabetes mellitus: South Asian Federation of Endocrine Societies consensus statement.An evidence-based practice-oriented review focusing on canagliflozin in the management of type 2 diabetes.Canagliflozin in the treatment of type 2 diabetes: an evidence-based review of its place in therapy.Benefits/risks of sodium-glucose co-transporter 2 inhibitor canagliflozin in women for the treatment of Type 2 diabetesSafety of ipragliflozin in elderly Japanese patients with type 2 diabetes mellitus (STELLA-ELDER): Interim results of a post-marketing surveillance study.Are SGLT2 inhibitors reasonable antihypertensive drugs and renoprotective?Oral anti-diabetic drugs and fracture risk, cut to the bone: safe or dangerous? A narrative review.SGLT2 inhibition: efficacy and safety in type 2 diabetes treatment.Sotagliflozin as a potential treatment for type 2 diabetes mellitus.Insulin resistance, role of metformin and other non-insulin therapies in pediatric type 1 diabetes.Acid-base and electrolyte disorders associated with the use of antidiabetic drugs.Diabetes and disordered bone metabolism (diabetic osteodystrophy): time for recognition.Role of SGLT2 inhibitors in the treatment of type 2 diabetes mellitus.The effects of canagliflozin, a sodium glucose co-transporter 2 inhibitor, on mineral metabolism and bone in patients with type 2 diabetes mellitus.Impact of empagliflozin in patients with diabetes and heart failure.Lack of evidence for a harmful effect of sodium-glucose co-transporter 2 (SGLT2) inhibitors on fracture risk among type 2 diabetes patients: a network and cumulative meta-analysis of randomized controlled trials.SGLT2 inhibitors in the management of type 2 diabetes.Empagliflozin for Type 2 Diabetes Mellitus: An Overview of Phase 3 Clinical Trials.Update review of the safety of sodium-glucose cotransporter 2 inhibitors for the treatment of patients with type 2 diabetes mellitus.The potential of SGLT2 inhibitors in phase II clinical development for treating type 2 diabetes.SGLT2 Inhibitors: Benefit/Risk Balance.SGLT2 Inhibition in the Diabetic Kidney-From Mechanisms to Clinical Outcome.Pharmacokinetic and pharmacodynamic drug evaluation of tofogliflozin for the treatment of type 2 diabetes.Effects of Incretin-Based Therapies and SGLT2 Inhibitors on Skeletal Health.Diabetes Drug Effects on the Skeleton.Evaluation of the pharmacokinetics, pharmacodynamics and clinical efficacy of empagliflozin for the treatment of type 2 diabetes.Effects of sodium-glucose co-transporter 2 inhibitors on metabolism: unanswered questions and controversies.Bone Fractures with Sodium-Glucose Co-transporter-2 Inhibitors: How Real is the Risk?
P2860
Q26749281-C3E1C9B0-FC98-4908-A7DB-B1307BB0DE07Q26750278-DEDE7A89-5733-442B-BC43-A6D1AFD02014Q30234622-63F84657-CFAE-4BAE-BBF8-DBB6A8C0D75CQ33571597-615D7668-0EB4-496B-952D-AEC31E75C205Q33625568-A0C8F3C2-3905-4607-BC76-5C3FE822AFF5Q33766770-DA4DB7E2-ED60-4FB8-AD22-B119C1B83684Q33871397-C4135CC2-EEF0-4417-9079-483AA75C544CQ33890770-D462965B-C653-449B-9A9B-876C21EEFA41Q36372598-E9148FBB-C6BC-4AD6-AA5C-3FA1D1501F6CQ36431654-FBAD4E7F-D628-42A4-9D7C-1394ECF6ED4AQ36960633-7FD15D1F-FECD-456C-80E9-AC64CDD20305Q37221508-8A96F2BC-3651-44F4-8E9F-62228866E131Q37588847-9F301F59-45C0-4885-B7B4-028188E16FCCQ37661798-A27860CC-269E-4041-BE7D-8BA9F5ABC590Q37712199-223CFB56-B717-4298-954D-96320BFB7292Q37741752-43D24FCE-770C-4195-8A13-C1A54055EB92Q38396879-14F96BED-B878-496C-96D8-2AACDD521B39Q38429845-5CE58C40-6BA4-4C4C-A0BA-812BAE1ABB4BQ38441017-0F4E026D-2FBE-4A66-9E85-71A959578697Q38619164-461F4DCC-C3CF-4B1A-A850-1831A70CF59AQ38628037-CF5A6AB1-4F86-4D2F-A910-AF00307F6ED5Q38642435-33C31F21-9FFB-41ED-9590-6ED5167CB12AQ38658251-8AB5C757-E26F-4BCF-8930-E818893D7902Q38776127-3D9FB8C9-3CD8-48D8-9C61-D1875A9FCDAEQ38796262-56ACDE3B-46A1-4411-B302-5DDB10F14BBEQ38798654-99D22E00-3599-4B4B-9CA3-F04297286197Q38822815-56768EB7-F86E-4729-BF56-405C1EFFF149Q38842559-91C2128A-EC32-451A-8AF6-6BD5DED6C75AQ38857523-FCCBC0CF-DD4F-4D5A-9CB4-719427EFAC39Q38863649-A861CE0E-5ACF-4560-9814-7624C5B70DD7Q38906041-CA119A9B-50D7-4101-B52C-D86AE8CC87B1Q38908779-3A33DC9C-B647-4635-B6F6-8A5EAC6AE2AAQ38931842-06716620-7B7D-4BDB-842D-BAF84D96F6D2Q38932322-01320F50-97D5-4A15-BD45-6A68969C49A5Q38936746-0218BD7D-B88D-4879-8B47-050624AA29FBQ38973384-E351CD57-7207-4C75-AA7B-B0CADD786189Q38999214-808D1EC9-6FA6-441A-92EC-A13F366E76C4Q39000172-3DBCCDDE-44A8-4CBC-856C-D27E8928E487Q39000587-44CDA1C4-F662-49B7-AB47-6039DF314A31Q39003573-A097B23B-0078-45D1-911C-29E934976143
P2860
description
2014 nî lūn-bûn
@nan
2014年の論文
@ja
2014年論文
@yue
2014年論文
@zh-hant
2014年論文
@zh-hk
2014年論文
@zh-mo
2014年論文
@zh-tw
2014年论文
@wuu
2014年论文
@zh
2014年论文
@zh-cn
name
Possible adverse effects of SGLT2 inhibitors on bone
@en
type
label
Possible adverse effects of SGLT2 inhibitors on bone
@en
prefLabel
Possible adverse effects of SGLT2 inhibitors on bone
@en
P2093
P2860
P1476
Possible adverse effects of SGLT2 inhibitors on bone
@en
P2093
Jenny E Blau
Kristina I Rother
Simeon I Taylor
P2860
P356
10.1016/S2213-8587(14)70227-X
P577
2014-12-16T00:00:00Z